Achillion Pharmaceuticals, Inc. to incur higher cost on R&D activities in 2011

Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) traded flat in the last three
trading sessions after reporting its fourth quarter and fiscal ended December
31, 2010 results on March 2, 2011. The Company's net loss for the reported
quarter reduced to $6.2 million from $6.7 million in 2009 mainly on the grants
under the Qualified Therapeutic Discovery Program, or QTDP, a federal program
administered through the National Institutes of Health. Revenues for the quarter
increased to $2 million as compared to $0.061 million reported in the prior year
period. But the Company's expenditure on research and development particularly
on the clinical testing of the Companys HCV protease inhibitor, ACH-1625, as
well as late stage preclinical testing of the Companys HCV NS5A inhibitor,
ACH-2928, and its pan-genotypic protease inhibitor, ACH-2684 also increased to
$6.1 million from $4.9 million in the prior year period. Total revenues for the
fiscal year was reported at $2.4 million as compared to ($2.94) million in 2009
primarily due to the QTDP grants while the Company also incurred higher cost due
to its increased clinical trial activities. Net loss incurred only slightly by
0.4 million to $25.5 million as compared to net loss of $25.9 million in 2009.
The Company is anticipating net loss of $65-$70 per diluted share on higher
research and development expenses of $30-$33 million in 2011. Achillion
Pharmaceuticals, Inc. trade closed at $6 after trading on a volume of 490.265K
shares as compared to the average trading volume of 240.896K shares. Its market
capitalization stands at $350.10 million on 58.35 million outstanding shares.
Achillion is an innovative pharmaceutical company dedicated to bringing
important new treatments to patients with infectious disease. Disclaimer: The
assembled information distributed by epicstockpicks.com is for information
purposes only, and is neither a solicitation to buy nor an offer to sell
securities. Epicstockpicks.com does expect that investors will buy and sell
securities based on information assembled and presented herein.
EpicStockPicks.com will not be responsible in any way for or accept any
liability for any losses arising from an investor's reliance on or use of
information obtained from our website or emails. PLEASE always do your own due
diligence, and consult your financial advisor.